Thndr Claps
  • U.S.
  • Egypt
  • Saudi
  • Thinkers
  • Arabic
No Result
View All Result
Thndr Claps

Thndr Claps » U.S. Claps » Health & Pharma💉 » Novavax loses its optimism for 2022 📉

Novavax loses its optimism for 2022 📉

by Omar El Shorafa
August 9, 2022
Novavax, NASDAQ, Claps

The Clap
Novavax (NASDAQ: NVAX) lowered its revenue expectations by half for 2022.

The Deets
Novavax cut their expected sales for 2022 by 50%, expecting to generate $2 billion – $2.3 billion instead of $4 billion – $5 billion.

Novavax recorded a loss of $6.53 per share, with revenue at $186 million for Q2 2022.

They justified slashing this forecast as no new COVID-19 vaccine sales are expected for 2022.

More about Novavax
Novavax was one of the companies in the race to create a COVID-19 vaccine. They fell behind in that race when they struggled to set up a manufacturing base. 

The demand for COVID-19 shots has significantly faltered as most people have already been vaccinated. This hurt Novavax’s revenue for Q2 2022.

  • Click to share on Facebook (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)

Related Posts

Intel, Chips, NASDAQ
Tech 📲

An underwhelming quarter from Intel 📉

by Omar El Shorafa
January 27, 2023
Claps, Health
Tech 📲

Amazon offer medical subscription service 💊

by Omar El Shorafa
January 25, 2023
Claps, Tech
Tech 📲

Microsoft posts bitter-sweet quarter 💻

by Omar El Shorafa
January 25, 2023
Claps, Tech
Tech 📲

Google to begin layoffs ✂️

by Omar El Shorafa
January 23, 2023
Claps, NASDAQ, Alphabet
Tech 📲

Google spreading its costs

by Omar El Shorafa
January 20, 2023
Claps, NASDAQ, Tech
Tech 📲

Netflix raking in new subscribers 📺

by Omar El Shorafa
January 20, 2023

Website

Community

Blog

Learn

© Thndr. All rights reserved

No Result
View All Result
  • U.S.
  • Egypt
  • Saudi
  • Thinkers
  • Arabic

Disclaimer: Thndr does not provide investment advice, individual investors are responsible for their own decisions or can seek independent advice. The value of investments can go up and down. Thndr is a trading name of Thndr Securities Brokerage which is authorised and regulated by the Financial Regulatory Authority (FRA). Registered in Egypt (no. 804)..© Thndr. All rights reserved

 

Hello👋 We want you to be able to express your opinions on anything and everything finance and economics related to the Egyptian and US markets.

This is why we introduced Thndr Thinkers💭

Let’s go through some housekeeping notes before you jump into publishing your article to all Thndr Claps readers!

Type of Content📝 We want to see market-relevant content that shows good analysis, please! Base your articles on facts 

Don’t be shy, explain🗣 Flex your knowledge to us, and we’ll share it with all the readers!

Be Original🙏 Please don’t copy. No one likes a copycat. All submissions are welcome as long as they’re yours 

Make your title attractive🤩 A title is like the cover of your book. Attractive enough to make you look at the book but also clear enough to tell you what the book is about.

Clean🧹 We’re all humans and we all make mistakes. But please try and clean up the article so it’s clear for all the readers 

No promotional content🚫 We don’t publish promotional content.

Any questions about becoming a Thndr Thinker? Email thndrclaps@thndr.app and we’d be happy to help!

Normally, your article will be published within 24 hours of submission (if you followed the guidelines)